Fadini GP, et al. - In this multicenter retrospective study on diabetes outpatient clinics, the researchers compared the effectiveness of DPP-4 inhibitors (DPP4i) vs gliclazide extended release. Change from baseline in HbA1c was the primary endpoint. Changes in fasting plasma glucose, body weight, and systolic blood pressure were the secondary endpoints. They used propensity score matching (PSM) to generate comparable cohorts to perform outcome analysis. It was observed in the findings that starting a DPP4i allows better glycemic control than starting low-dose gliclazide in routine clinical practice, particularly for patients who failed other glucose-lowering medications or were on basal insulin.